Remogliflozin etabonate

Drug Profile

Remogliflozin etabonate

Alternative Names: 189075; BHV 091009; GSK 189075; KGT-1681; Remo; Remogliflozin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Avolynt; BHV Pharma
  • Class Antihyperglycaemics; Glucosides; Pyrans; Pyrazoles
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Phase I Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 12 Jan 2017 BHV Pharma completes a phase II trial for Type-2 diabetes mellitus in USA (NCT02537470)
  • 15 Dec 2016 Biomarkers information updated
  • 09 Aug 2016 Avolynt plans the pivotal phase II/III/IV REIN trial in patients with biopsy-confirmed Non-alcoholic steatohepatitis in 2017 (Avolynt pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top